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Introduction
Lung cancer treatment landscape has completely changed 
in the last decade. The introduction of druggable targets in 
the therapeutic scenario gave the opportunity to significantly 
improve the outcomes in the most lethal malignant disease. 
EML4-ALK translocation represents a story of success in drug 
development. The discovery of the aberration in tumors of 
patients with lung cancer in 2007 (1) soon translated into a 
rapid approval of the first ALK tyrosine kinase inhibitor (TKI), 
crizotinib (2), and the subsequent early arrival of second and 
third generation TKIs, all happening in roughly a decade. The 
current standard for the identification of the target necessarily 
implies identification of rearrangement in the tumor tissue either 
by FISH or immunohistochemistry. Unfortunately, despite the 
efforts, a big number of non-small cell lung cancer (NSCLC) 
patients have no tissue available for determination. The isolation 
of ctDNA is a novel approach, but still not validated for EML4-
ALK translocation (3,4). Exosomes, new members of the liquid 
biopsy family, carrying genetic material represent an important 
tool for biomarkers discovery (5). Our group has identified, for 
the first time, EML4-ALK translocation in exosomes (ExoALK), 
using a next generation sequencing technique. 
Perspective
EML4-ALK translocation identification in RNA exosomal cargo 
(ExoALK) in NSCLC patients: a novel role for liquid biopsy 
Pablo Reclusa1,2#, Jean-François Laes3#, Umberto Malapelle4, Anna Valentino5, Danilo Rocco6,  
Ignacio Gil-Bazo7,8, Christian Rolfo1,9
1Phase I-Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital (UZA) & Center for Oncological Research of Antwerp 
(CORE) Antwerp University, Antwerp, Belgium; 2Department of Surgical, Oncological and Stomatological Disciplines, University of Palermo, Palermo, 
Italy; 3OncoDNA SA, 6041 Gosselies, Belgium; 4Department of Public Health, University of Naples Federico II, Naples, Italy; 5Gene Expression and 
Molecular Genetics Laboratory, Institute of Biosciences and BioResources, National Council of Research, CNR, Naples, Italy; 6Oncology Unit, A.O.R.N. 
Vincenzo Monaldi – Ospedale dei Colli, Naples, Italy; 7Department of Oncology, Clínica Universidad de Navarra & Navarra Health Research Institute 
(IDISNA), Pamplona, Spain; 8Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; 9University of Maryland Marlene 
and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA
#These authors contributed equally to this work.
Correspondence to: Prof. Christian Rolfo, MD, PhD, MBA. University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, 
Baltimore, MD, USA. Email: christian.rolfo@umm.edu.
Abstract: The introduction of druggable targets has significantly improved the outcomes of non-small cell lung 
cancer patients (NSCLC). EML4-ALK translocation represents 4–6% of the druggable alterations in NSCLC. 
With the approval of Crizotinib, first discovered drug for the EML4-ALK translocation, on first line treatment 
for patients with detected mutation meant a complete change on the treatment landscape. The current standard 
method for EML4-ALK identification is immunohistochemistry or FISH in a tumor biopsy. However, a big number 
of NSCLC patients have not tissue available for analysis and others are not suitable for biopsy due to their physical 
condition or the location of the tumor. Liquid biopsy seems the best alternative for identification in these patients 
that have no tissue available. Circulating free RNA has not been validated for the identification of this mutation. As a 
complementary tool, exosomes might represent a good tool for predictive biomarkers study, and due to their stability, 
they preserve the genetic material contained in them. Our group has described for the first time the translocation 
EML4-ALK in RNA isolated from exosomes derived from NSCLC patients using next generation sequencing.
Keywords: Exosomes; liquid biopsy; ALK translocation; non-small cell lung cancer (NSCLC); biomarkers
Submitted Oct 07, 2018. Accepted for publication Oct 17, 2018.
doi: 10.21037/tcr.2018.11.35
View this article at: http://dx.doi.org/10.21037/tcr.2018.11.35
78
S77Translational Cancer Research, Vol 8, Suppl 1 January 2019
© Translational Cancer Research. All rights reserved.   Transl Cancer Res 2019;8(Suppl 1):S76-S78 tcr.amegroups.com
Material and methods
Patients selection
Patients with confirmed diagnosis of stage IIIB–IV 
NSCLC, naïve or under treatment with known ALK status 
were eligible for this proof of concept study. EML4-ALK 
translocation in tumor tissue was performed by FISH 
according to the clinical records of the patients. Patients 
gave their informed consent before the sample collection 
according to the institution regulation. Blood samples were 
collected only at a single point. Clinical data were collected 
from the electronic medical records. Samples and data from 
patients included in the study were provided by the Biobank 
of the University of Navarra (Reg#: B_0000612) and 
were processed following standard operating procedures 
approved by the Ethical and Scientific Committees. The 
trial was approved by the Antwerp University Hospital 
ethical committee n. 14/17/206.
Exosomal RNA isolation
The exosomal RNA cargo was extracted from 1 mL of plasma 
using ExoRNeasy Kit from QIAGEN with a modification of 
the original protocol to avoid loss of material and volume. This 
includes 3 centrifugations of 5' × 500 g, 15' × 3,000 g and 30' × 
10,000 g instead of the filtration in 0.8 μM (Figure 1).
Next generation sequencing
The fusions were analyzed using the Ion Ampliseq RNA 
Fusion Lung Cancer panel (Thermo Fisher Scientific, 
Waltham, USA). The primers used for amplification were 
then partially digested by the Pfu enzyme. The product of 
digestion was ligated with corresponding barcoded adapters 
and purified using Ampure Beads (Agilent Genomics Inc). 
The product of purification was amplified for 5 more cycles 
and subsequently purified using Ampure Beads. Ten pM of 
each library was loaded into the IonChef system (Thermo 
Fisher Scientific, Waltham, USA) for the emulsion polymerase 
chain reaction (PCR) and then loaded in the chip.
The quality of the data was assessed using the Torrent suite 
software (Thermo Fisher Scientific, Waltham, USA) associated 
with the sequencing machine. The minimum read length for 
fusion detection was set to 50 bp (base pair). We consider that 
under this value the reads were too short to overlap targeted 
fusion breakpoint. In addition, to assess the detection quality, 
at least 20,000 reads were required per sample (Figure 1).
Results
A total of 19 patients with plasma samples were included in 
the study, 16 of them harboring EML4-ALK translocations 
in tissue. In 1 mL of plasma, the RNA concentration ranged 
from 0.5 to 121 mg/mL. In total, 17 patients were finally 
eligible for extracellular vesicles analysis. In nine patients, we 
were able to identify the translocation in the exosomal RNA. 
The concordance between tissue and exosomes was 64% (9 
out of 14 patients). All three patients being negative for the 
fusion gene in tissue resulted also negative in the ExoALK 
analysis, representing a specificity of 100% (Table 1). 
No correlation was found between the RNA yield and the 
type of sample or its clinical variables. 
Figure 1 Schematic representation of ExoALK proof of concept study.
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Discussion
Here we demonstrate for the first time that EML4-ALK 
translocation detection in exosomes of NSCLC patients is 
feasible, with a high sensitivity and specificity. The exosomal 
analysis represents an opportunity for patients therapeutic 
selection with a minimal invasive procedure, easy to 
perform and with an affordable cost. The development 
of new techniques with a direct detection of the fusion by 
capture instead of by amplification would be the key to 
improve the sensitivity of ExoALK in the future.
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